### Results Reality Check

Generated: 2025-10-30

## 1) Dependency Analysis (cancer_type_rankings.csv)

- Distribution (combined_score_mean): min -0.2241, max -0.0501, mean -0.0915
- Threshold buckets (approx, using combined_score_mean):
  - STRONG (< -0.5): 0 cancer types
  - MODERATE (-0.3 to -0.5): 0 cancer types
  - WEAK (> -0.3): 58 cancer types
- Honest assessment: Targets appear context-specific with overall weak average dependency magnitudes; not broadly essential.

## 2) Synthetic Lethality (synthetic_lethality_results.csv)

- Significant hits (p < 0.10): 11 of 44 combinations
- Strongest effect size: Δ=+0.1164 (PTEN × CLK4), p=2.31e-07
- Most significant p-value: 2.31e-07 (PTEN × CLK4)
- Honest assessment: Signals exist but effect sizes are modest; evidence is suggestive rather than definitive.

## 3) Literature Support

- Not yet executed programmatically. No counts available.
- Honest assessment: Pending; cannot claim strong literature support yet.

## 4) Expression Analysis

- Not yet saved to processed outputs.
- Honest assessment: Pending; correlation unknown.

## 5) Reality Check (Direct Answers)

- Are these targets broadly essential? → NO
- Did we find strong mutation-based synthetic lethality? → WEAK SIGNALS
- Any clear winner cancer types? → YES (rare cancers top list: Extra Gonadal Germ Cell Tumor, Non-Seminomatous Germ Cell Tumor, Merkel Cell Carcinoma; note small sample sizes)
- Strongest evidence dimension? → Dependency (cross-validated by rankings and cell line negatives)
- What to focus on now? → Strengthen multi-dimensional evidence: expression correlation, copy number impact, and targeted literature review; emphasize cancer-type and mutation-context specificity.

## 6) What the Data Is Actually Telling Us

- Multi-target combined dependency is generally mild; no broad essentiality.
- TBK1 and STK17A show more consistent negative dependencies than MYLK4.
- Several mutation × target pairs show statistically significant differences but small effect sizes.
- Top-ranked cancer types are rare; confidence limited by small n.
- Additional modalities (expression, copy number) are needed to prioritize indications with stronger evidence.
